Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
Follow BMY
Bristol Myers Squibb Company (BMY) Return on equity
Bristol Myers Squibb Company's return on equity over the twelve months to 30 June 2026 was 46.6%, up 6.2 percentage points from fiscal 2025 (40.4%). Over the past ten years it has ranged from −39.0% (fiscal 2024) to 40.4% (fiscal 2025) — the current reading is the highest in ten years. That is above the Drug Manufacturers General industry median of 5.87% and above the Healthcare sector median of −31.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 40.4% | 79.44 |
| FY2024 | −39.0% | (65.49) |
| FY2023 | 26.5% | 7.63 |
| FY2022 | 18.9% | (0.08) |
| FY2021 | 18.9% | 39.06 |
| FY2020 | −20.1% | (30.58) |
| FY2019 | 10.5% | (27.43) |
| FY2018 | 37.9% | 30.74 |
| FY2017 | 7.14% | (21.83) |
| FY2016 | 29.0% | 18.33 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| AMGN Amgen Inc. compare | 91.5% |
| NVO Novo Nordisk A/S compare | 60.8% |
| BMY Bristol Myers Squibb Company | 46.6% |
| GSK GSK PLC Sponsored ADR compare | 30.7% |
| NVS Novartis AG compare | 30.4% |
| AZN AstraZeneca PLC compare | 22.0% |
| SNY Sanofi compare | 5.87% |
| PFE Pfizer Inc. compare | 4.97% |
| GILD Gilead Sciences, Inc. compare | −20.7% |
| Drug Manufacturers General industry median | 5.87% |
| Healthcare sector median | −31.3% |
| Market median | 1.35% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement